Title: Evaluation of anti-anxiety and anti-depressant effect of palonosetron in Swiss albino mice

Biography:

Dr. Jyoti Sharma, currently working as Assistant Professor in the Department of Pharmacology, PGIMS, Rohtak. Actively involved in teaching of MD, MBBS, BDS & Allied Health Sciences. Work profile also includes Detection & reporting of ADRs, Quality assurance (e.g. completeness and integrity of data) of uploaded ADRs, Assessment of Individual Case Safety Reports, Causality assessment, Clinical and experimental Research. Has a total of 7 years of teaching experience. Recipient of Dr.  R.  D  Kulkarni  Award  for  Third  position  in  Poster  presentation  at  South  Asian  College  of  Clinical  Pharmacology  an  Affiliate  of  American  College  of  Clinical  Pharmacology in  Eleventh  Annual  Conference  “Clinical  Pharmacology:  Contributing  to  Global  Health and  Policies”  held  from  29th  April  –  2nd  May  2018. The above study was done to find out the anxiolytic and antidepressant effect of Palonosetron as no studies have been found till date.

Abstract

Background: Depression and anxiety remain serious problems in given unexpected circumstances like Covid-19. Serotonin is one of the most important neurotransmitters influencing mental health and a potential target for pharmacological treatments. 5HT₃ receptor antagonists like ondansetron; mainly used for management of acute & delayed cancer chemotherapy induced emesis, has shown anxiolytic and antidepressant effect in various studies. Another 5HT₃ antagonist; Palonosetron approved for delayed cancer chemotherapy induced emesis, has yet not been studied for anxiolytic and antidepressant effects. Material & Methods: Light-dark compartment model was used for anti-anxiety effect evaluation and Swim despair test was used for evaluation of anti-depressant effect. Swiss albino mice were used and randomly divided in 5 groups of 6 each to receive following 5 treatments: Group 1Control i.e normal saline (0.1 ml/10 g of body weight i.p.), Group 2: Diazepam (1mg/kg i.p), Group 3: Fluoxetine (18mg/kg i.p), Group 4:  Palonosetron (0.025 mg/kg i.p), Group 5: Palonosetron (0.05mg/kg i.p) in each animal model. In light-dark compartment model efficacy was assessed at end of 15, 30, 60, 120, 180 & 300mins by observing time spent in light compartment and number of transitions made between both compartments. In Swim despair test efficacy was assessed by recording of immobility period after 1 hr & 24 hrs of drug administration. Results: Time spent in the light compartment at the end of 30, 60 and 120 min with palonosetron (0.05mg/kg) was statistically significant more as compared to control & fluoxetine.  No of transitions made between both compartments also increased with palonosetron (0.05mg/kg) at the end of 15, 30, 60 & 120 mins as compared to control and fluoxetine groups. In Swim despair test palonosetron (0.05mg/kg) showed statistically significant antidepressant activity as compared to control and fluoxetine group at 1 hr & 24 hrs respectively. Conclusion: Palonosetron (0.05mg/Kg) possesses significant antidepressant & anti-anxiety activity in animal models.  
Recent Publications (minimum 5)

1. Parekar SM, Dharmadhikari SC, Jaju JB, Pawar GR, Solunke R. Evaluation of antidepressant activity of ondansetron alone and in combination with fluoxetine-an experimental study. Int J Basic Clin Pharmacol 2016;5:90-7.
2. Kurhe Y , Mahesh R.  Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission. Pharmacol Biochem Behav. 2015;136:107-16.
3. Lourdu JA, Shanthi M, Meher AR. Anxiolytic effect of Ondansetron, a 5-HT3 Antagonist on male albino mice in the Elevated plus maze. Research Journal of Pharmaceutical, Biological & Chemical Sciences. 2013;4:1665-9.
4. Kurhe YV, Mahesh R, Gupta D. Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benz[d]thiazol-2-yl)-3 ethoxyquinoxalin-2 carboxamide (6k) using battery tests for anxiety in mice. Indian J Pharmacol. 2014;46(1):100-4.
5. Garibova TL , Voronina TA,  KraÄ­neva VA, Val'dman EA.  The anxiolytic effect of ondansetron and its capacity to eliminate the benzodiazepine abstinence syndrome in rats. Eksp Klin Farmakol. 1999;62(6):16-9.